Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Marta R Couto (Author) FMUP; Pereira Terra, P (Author) Other; Quelhas Santos, J (Author) FMUP; Silva Pereira, C (Author) Other; Albino Teixeira, A (Author) Other; Sousa, T (Author) FMUP

Journal

Title: Frontiers in Physiology

Vol. 12

ISSN: 1664-042X

Publisher: Frontiers Media

Indexing

ISI Web of Knowledge - 81 Citations

Scopus - 89 Citations

Other information

Authenticus ID: P-00V-H7Z

DOI: 10.3389/fphys.2021.746494

Abstract (EN): Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient's inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.</p>

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 25